Drug Information

Drug General Information
Drug ID
D0C1JP
Former ID
DCL001065
Drug Name
AEG35156
Drug Type
siRNA drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1/2 [522458]
Therapeutic Class
siRNA
Company
Aegera Therapeutics
CAS Number
CAS 928841-57-0
Target and Pathway
Target(s) mRNA of Inhibitor of apoptosis protein Target Info [537563]
KEGG Pathway NF-kappa B signaling pathway
Ubiquitin mediated proteolysis
Apoptosis
Focal adhesion
Toxoplasmosis
HTLV-I infection
Pathways in cancer
Small cell lung cancer
PANTHER Pathway Apoptosis signaling pathway
Pathway Interaction Database p75(NTR)-mediated signaling
BMP receptor signaling
Caspase Cascade in Apoptosis
TGF-beta receptor signaling
Reactome SMAC binds to IAPs
SMAC-mediated dissociation of IAP:caspase complexes
Deactivation of the beta-catenin transactivating complex
RIPK1-mediated regulated necrosis
Regulation of TNFR1 signaling
TNFR1-induced NFkappaB signaling pathway
Regulation of necroptotic cell death
WikiPathways Copper homeostasis
Focal Adhesion
Apoptosis
Intrinsic Pathway for Apoptosis
Apoptosis Modulation and Signaling
NOD pathway
References
Ref 522458ClinicalTrials.gov (NCT00768339) A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas. U.S. National Institutes of Health.
Ref 537563Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.